Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Asset Writedowns and Impairment (2021 - 2025)

Historic Asset Writedowns and Impairment for GeneDx Holdings (WGS) over the last 5 years, with Q3 2025 value amounting to $29000.0.

  • GeneDx Holdings' Asset Writedowns and Impairment changed N/A to $29000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $72000.0, marking a year-over-year increase of 8000.0%. This contributed to the annual value of $180000.0 for FY2024, which is 9826.96% down from last year.
  • Latest data reveals that GeneDx Holdings reported Asset Writedowns and Impairment of $29000.0 as of Q3 2025.
  • Over the past 5 years, GeneDx Holdings' Asset Writedowns and Impairment peaked at $209.4 million during Q4 2022, and registered a low of -$1.3 million during Q3 2021.
  • For the 5-year period, GeneDx Holdings' Asset Writedowns and Impairment averaged around $20.2 million, with its median value being $645000.0 (2021).
  • In the last 5 years, GeneDx Holdings' Asset Writedowns and Impairment skyrocketed by 2069572.99% in 2022 and then plummeted by 9811.32% in 2024.
  • GeneDx Holdings' Asset Writedowns and Impairment (Quarter) stood at $1.0 million in 2021, then soared by 20695.73% to $209.4 million in 2022, then plummeted by 96.05% to $8.3 million in 2023, then tumbled by 99.48% to $43000.0 in 2024, then plummeted by 32.56% to $29000.0 in 2025.
  • Its last three reported values are $29000.0 in Q3 2025, $43000.0 for Q4 2024, and $40000.0 during Q1 2024.